DK2396659T3 - RBM3-protein i testikelkræftdiagnostik og -prognostik - Google Patents

RBM3-protein i testikelkræftdiagnostik og -prognostik

Info

Publication number
DK2396659T3
DK2396659T3 DK10704927.2T DK10704927T DK2396659T3 DK 2396659 T3 DK2396659 T3 DK 2396659T3 DK 10704927 T DK10704927 T DK 10704927T DK 2396659 T3 DK2396659 T3 DK 2396659T3
Authority
DK
Denmark
Prior art keywords
prognosis
testicular cancer
cancer diagnosis
rbm3 protein
rbm3
Prior art date
Application number
DK10704927.2T
Other languages
English (en)
Inventor
Karin Jirstroem
Jakob Eberhard
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of DK2396659T3 publication Critical patent/DK2396659T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK10704927.2T 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik DK2396659T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
US16996309P 2009-04-16 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
US23376909P 2009-08-13 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis
PCT/EP2010/051935 WO2010092187A1 (en) 2009-02-16 2010-02-16 Rbm3 protein in testicular cancer diagnostics and prognostics

Publications (1)

Publication Number Publication Date
DK2396659T3 true DK2396659T3 (da) 2013-03-04

Family

ID=41718882

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10704927.2T DK2396659T3 (da) 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik
DK10704928.0T DK2396660T3 (da) 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10704928.0T DK2396660T3 (da) 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi

Country Status (9)

Country Link
US (3) US8632984B2 (da)
EP (4) EP2396657B1 (da)
JP (3) JP5669757B2 (da)
CN (1) CN102334032B (da)
AU (4) AU2009339802B2 (da)
CA (3) CA2749349A1 (da)
DK (2) DK2396659T3 (da)
HK (1) HK1166371A1 (da)
WO (5) WO2010091763A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8632984B2 (en) * 2009-02-16 2014-01-21 Atlas Antibodies Ab RBM3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
EP2630498A4 (en) * 2010-10-22 2014-10-01 Vermillion Inc PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) * 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
WO2007027906A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
US8632984B2 (en) * 2009-02-16 2014-01-21 Atlas Antibodies Ab RBM3 as a marker for malignant melanoma prognosis
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer

Also Published As

Publication number Publication date
CN102334032A (zh) 2012-01-25
AU2010212769A1 (en) 2011-07-28
US20120034317A1 (en) 2012-02-09
WO2010092184A1 (en) 2010-08-19
CA2749350A1 (en) 2010-08-19
EP2396657B1 (en) 2013-11-13
US8632984B2 (en) 2014-01-21
JP5767116B2 (ja) 2015-08-19
WO2010092187A1 (en) 2010-08-19
EP2396657A1 (en) 2011-12-21
HK1166371A1 (en) 2012-10-26
US8747910B2 (en) 2014-06-10
CA2749349A1 (en) 2010-08-19
DK2396660T3 (da) 2013-10-28
AU2010212772B2 (en) 2014-07-17
AU2010212772A1 (en) 2011-07-28
US20120269764A1 (en) 2012-10-25
CN102334032B (zh) 2015-01-28
CA2749392A1 (en) 2010-08-19
AU2009339802A1 (en) 2011-07-28
EP2396659B1 (en) 2012-11-21
EP2396346B1 (en) 2013-04-03
JP2012518164A (ja) 2012-08-09
AU2010212769C1 (en) 2014-10-09
JP2012518162A (ja) 2012-08-09
WO2010091763A1 (en) 2010-08-19
JP5611986B2 (ja) 2014-10-22
JP5669757B2 (ja) 2015-02-18
EP2396346A1 (en) 2011-12-21
EP2396659A1 (en) 2011-12-21
WO2010092190A2 (en) 2010-08-19
AU2010212764A1 (en) 2011-07-28
JP2012518163A (ja) 2012-08-09
EP2396660B1 (en) 2013-07-24
AU2010212769B2 (en) 2014-07-17
WO2010092190A3 (en) 2010-11-04
WO2010092182A1 (en) 2010-08-19
EP2396660A2 (en) 2011-12-21
US20120058202A1 (en) 2012-03-08
AU2010212764B2 (en) 2014-07-17
AU2009339802B2 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
DK2396659T3 (da) RBM3-protein i testikelkræftdiagnostik og -prognostik
NL350111I2 (nl) fenpicoxamid en prothioconazool
HK1179631A1 (zh) 蛋白和其用途
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
BRPI1004572A2 (pt) "fusões genéticas recorrentes em câncer
EP2480983A4 (en) PROCESSING TRANSACTIONS IN GRAPHIC-BASED APPLICATIONS
EP2547888A4 (en) TREATMENT OF FUEL AND WATER
IT1400121B1 (it) Copoliestere alifatico-aromatico e sue miscele.
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
SI2544682T1 (sl) Fitokanabinoidi pri zdravljenju raka
PL2366031T3 (pl) Metody sekwencjonowania w diagnostyce prenatalnej
EP2398820A4 (en) CANCER-TREATED PEPTIDES AND THEIR USE IN CANCER THERAPY
EP2748333A4 (en) DNA METHYLATION IN DIAGNOSTIC METHODS OF COLORECTAL CANCER AND BREAST
HK1168653A1 (en) A-fucosylation detection in antibodies a-
DK2563935T3 (da) In situ-hybridiseringsfremgangsmåde og -buffer
IL199618A0 (en) Novel antibodies and their use in diagnostic methods
EP2632939A4 (en) CANCER TARGETING PEPTIDES AND USES THEREOF IN THE TREATMENT AND DIAGNOSIS OF CANCER
DK2475362T3 (da) Cancerstamcellemålrettet og lægemiddelresistent cancerterapi
HK1164193A1 (zh) 抗體及其用途
IL224766A (en) Bard1 isoforms in lung and colorectal cancer and their uses
IT1394046B1 (it) Sarchiatrice con organi rotanti ad elementi ganciformi
EP2798065A4 (en) AT THE SAME TIME GEN-SILENCING AND SUPPRESSION OF GEN-SILENCING IN THE SAME CELL
EP2635579A4 (en) SYNTHETIC LETHALITY IN CANCER
EP2470903A4 (en) GENE AND POLYPEPTIDE ASSOCIATED WITH BREAST CANCER
AU331635S (en) Sweeper module